[Stereotactic body radiotherapy of oligometastases: Main pending trials and to come in France]. / Radiothérapie des oligométastases : principaux essais en cours et à venir en France.
Cancer Radiother
; 23(6-7): 496-499, 2019 Oct.
Article
em Fr
| MEDLINE
| ID: mdl-31471251
ABSTRACT
Stereotactic radiotherapy of oligometastases, mono- or hypofractionated, represents a fundamental change in the practice of the specialty as it was developed for a century. Despite the great heterogeneity of sites, techniques, and doses, most studies found a high local control rate, around 70 to 90% at 2 years, and reduced toxicity, around 5% of grade 3 at 2 years. Four main phase II and III trials are underway in France. Future research concerns the association of stereotactic radiotherapy with immunotherapy or different conventional chemotherapy protocols, the identification of the best clinical presentations, and optimization of fractionation and biological dose for poor prognosis localizations.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ensaios Clínicos Controlados Aleatórios como Assunto
/
Radiocirurgia
/
Ensaios Clínicos Fase III como Assunto
/
Ensaios Clínicos Fase II como Assunto
/
Neoplasias
Tipo de estudo:
Clinical_trials
/
Guideline
/
Prognostic_studies
Limite:
Humans
/
Male
País/Região como assunto:
Europa
Idioma:
Fr
Revista:
Cancer Radiother
Assunto da revista:
NEOPLASIAS
/
RADIOTERAPIA
Ano de publicação:
2019
Tipo de documento:
Article